Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 11;12:652136. doi: 10.3389/fphys.2021.652136

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Coskun, Elbahi, Al-Karagholi, Ghanizada, Sheykhzade and Ashina.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Effect of glibenclamide and placebo on middle cerebral artery (MCA) as changes in velocity (cm/s), n = 20. There was no difference in AUC₀_–_{240 min} for V_MCA between glibenclamide-CGRP and placebo-CGRP day. (B) Changes in end-tidal pCO₂ were monitored during MCA-measurements. There was no difference in changes in end-tidal PCO₂ (PetCO₂) between two experimental days. (C) Changes in superficial temporal artery (STA) in diameter (mm). There was no difference in AUC₀_–_{240 min} for STA between glibenclamide-CGRP and placebo-CGRP day. (D) Changes in radial artery (RA) diameter (mm). No changes in AUC₀_–_{240 min} for RA diameter was observed between glibenclamide-CGRP and placebo-CGRP day.